MyoKardia, Inc., a San Francisco, CA-based newly formed company that is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease, has raised $38m in Series A financing from Third Rock Ventures.
The company was founded in 2012 by:
– James Spudich, Ph.D., Professor of Biochemistry, Stanford University,
– Leslie Leinwand, Ph.D., Professor of Molecular, Cellular and Developmental Biology, University of Colorado,
– Christine Seidman, M.D., Professor of Medicine and Genetics, Harvard Medical School and Director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital, and
– Jonathan Seidman, Ph.D., Professor of Genetics, Harvard Medical School.
Led by interim CEO (and venture partner at Third Rock Ventures) Charles Homcy, M.D., MyoKardia has developed a proprietary drug discovery platform that brings together advances from the fields of cardiovascular genomics and heart muscle biology to enable scientists to target certain heart disease “at its source”. The company firstly focuses on Hypertrophic and dilated cardiomyopathies, which are the most common forms of heart muscle disease and the most common diagnosis leading to cardiac transplantation.